What the FDA decided on Imaavy for Warm autoimmune hemolytic anemia
The FDA approved Imaavy (nipocalimab-aahu) for warm autoimmune hemolytic anemia.
The first FDA-approved treatment for warm autoimmune hemolytic anemia, for patients 12 and older who are taking or have taken corticosteroids. Imaavy was already approved in 2025 for generalized myasthenia gravis. In the 24-week, 118-patient placebo-controlled trial (NCT04119050), 24% of patients on the 30mg/kg every-4-weeks dose had a durable hemoglobin response versus 8% on placebo; the 15mg/kg every-2-weeks dose did not beat placebo.
Who the Imaavy decision matters to
Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune disease in which the immune system makes antibodies, usually of the IgG type, that stick to red blood cells at normal body temperature, so the spleen destroys them early and anemia develops. It is the most common type of autoimmune hemolytic anemia.
Corticosteroids such as prednisone are the usual first treatment, and rituximab may be added. On August 24, 2026 the FDA approved Imaavy (nipocalimab) as the first medicine approved for wAIHA, for patients 12 and older who are taking or have taken corticosteroids.
Prevalence: About 1 to 3 new cases per 100,000 people each year, according to the FDA and NORD. Warm antibodies cause about 60-70% of all autoimmune hemolytic anemia (Orphanet, cited by NORD). See our full Warm Autoimmune Hemolytic Anemia page for current treatments, recruiting trials, and community resources.
How Imaavy works
Imaavy: anti-FcRn monoclonal antibody that reduces pathogenic IgG autoantibodies by blocking the neonatal Fc receptor. Our full Imaavy profile covers how it works, side effects in plain language, and its trial history.
Where Warm Autoimmune Hemolytic Anemia treatment stands today
Read our full Warm Autoimmune Hemolytic Anemia treatment summary
Several new approaches are in trials. Sanofi is recruiting adults for a Phase 3 trial of rilzabrutinib, a pill that blocks an enzyme called BTK, against placebo (NCT07086976), with sites in the U.S. and 17 other countries.
Phase 3 trials of ianalumab (Novartis) and obexelimab (Zenas BioPharma) have finished enrolling and are still running.
Early-stage studies are testing cell therapies in people whose wAIHA came back or did not respond to earlier treatment, including CRISPR Therapeutics' CTX112, which has U.S. sites.
Entry rules vary by trial. The Imaavy trial, for example, required wAIHA for at least 3 months, earlier or current treatment and a hemoglobin below 10g/dL, so bring your treatment history and recent blood counts.
A hematologist can tell you whether a trial or an approved treatment such as Imaavy fits you better.
The Warm Autoimmune Hemolytic Anemia page has every treatment and trial →Meanwhile, 11 Warm Autoimmune Hemolytic Anemia studies are recruiting or not yet recruiting
The FDA's decision does not end research on Warm Autoimmune Hemolytic Anemia. Of these, 10 test a treatment; the others follow patients over time. The most recently updated:
You'll hear about future FDA decisions and new recruiting trials for Warm Autoimmune Hemolytic Anemia. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.
We never share your email. Stop anytime from the link in every email. Privacy policy
Frequently asked questions
Has the FDA decided on Imaavy?
The FDA has already decided. It approved the application.
Details: the outcome and what it means are at the top of this page.
Source: FDA approval notice
What was Imaavy approved for?
The FDA approved Johnson & Johnson (Janssen)'s sBLA for Imaavy in Warm autoimmune hemolytic anemia.
What to know: The first FDA-approved treatment for warm autoimmune hemolytic anemia, for patients 12 and older who are taking or have taken corticosteroids. Imaavy was already approved in 2025 for generalized myasthenia gravis. In the 24-week, 118-patient placebo-controlled trial (NCT04119050), 24% of patients on the 30mg/kg every-4-weeks dose had a durable hemoglobin response versus 8% on placebo; the 15mg/kg every-2-weeks dose did not beat placebo.
How it works: Anti-FcRn monoclonal antibody that reduces pathogenic IgG autoantibodies by blocking the neonatal Fc receptor.
More: the Imaavy drug page explains it in plain language.
Is there already an FDA-approved treatment for Warm Autoimmune Hemolytic Anemia?
Yes. Trial Friend's drug list includes 1 FDA-approved drug for Warm Autoimmune Hemolytic Anemia.
Approved: Imaavy (nipocalimab).
Check: the Warm Autoimmune Hemolytic Anemia page also searches FDA drug labels for approved treatments.
What did the Imaavy trials show?
For warm autoimmune hemolytic anemia, in the 24-week ENERGY trial (NCT04119050) of 118 people, 24% on 30mg/kg every 4 weeks had a durable hemoglobin response against 8% on placebo; the 15mg/kg every-2-weeks dose did not beat placebo.
More: the Imaavy drug page has the full trial history and sources.
What are the side effects of Imaavy?
In myasthenia gravis, the most common side effects were respiratory tract infections, swelling in the legs or feet (peripheral edema), and muscle spasms. In warm autoimmune hemolytic anemia, they were peripheral edema, diarrhea, and fever.
More: the Imaavy drug page has the label's warnings in full.
How much will Imaavy cost?
Trial Friend does not list a price for Imaavy. What you pay depends on your insurance and on help from the drugmaker or a charity fund.
Drugmaker help: IMAAVY withMe Access Program.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Imaavy decision?
The FDA approved Imaavy for Warm autoimmune hemolytic anemia on August 24, 2026.
Next steps: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
Where this outcome comes from
The outcome on this page comes from FDA approval notice. This page rechecks against our calendar, which is re-verified daily.